MCID: SYS040
MIFTS: 22

Systemic Lupus Erythematosus 10

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 10

MalaCards integrated aliases for Systemic Lupus Erythematosus 10:

Name: Systemic Lupus Erythematosus 10 54 71 29
Systemic Lupus Erythematosus, Susceptibility to, 10 13
Sleb10 71

Classifications:



External Ids:

OMIM 54 612251
MedGen 40 C2677097
MeSH 42 D008180

Summaries for Systemic Lupus Erythematosus 10

UniProtKB/Swiss-Prot : 71 Systemic lupus erythematosus 10: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

MalaCards based summary : Systemic Lupus Erythematosus 10, is also known as systemic lupus erythematosus, susceptibility to, 10. An important gene associated with Systemic Lupus Erythematosus 10 is IRF5 (Interferon Regulatory Factor 5). The drugs Simvastatin and belimumab have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and kidney.

Description from OMIM: 612251

Symptoms & Phenotypes for Systemic Lupus Erythematosus 10

Clinical features from OMIM:

612251

Drugs & Therapeutics for Systemic Lupus Erythematosus 10

Drugs for Systemic Lupus Erythematosus 10 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
2
belimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 356547-88-1 5957 10451420
3
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
4
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
5
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
6
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 50-18-0, 6055-19-2 2907
8 Anticholesteremic Agents Phase 4,Phase 3,Phase 1,Early Phase 1
9 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Calcium, Dietary Phase 4,Phase 3,Phase 1,Early Phase 1
11 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 3,Phase 1,Early Phase 1
12 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Rosuvastatin Calcium Phase 4,Phase 1 147098-20-2
15 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
16 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
17 Estrogens Phase 4,Phase 2
18 Estrogens, Conjugated (USP) Phase 4
19 Hormone Antagonists Phase 4,Phase 2,Phase 3,Early Phase 1
20 Hormones Phase 4,Phase 2,Phase 3,Early Phase 1
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Early Phase 1
22 Adrenocorticotropic Hormone Phase 4
23 beta-endorphin Phase 4
24 Melanocyte-Stimulating Hormones Phase 4
25 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Vaccines Phase 4,Phase 1
28 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
29 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
30 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
31 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
32 Analgesics Phase 4,Phase 2,Phase 3
33 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
34 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Early Phase 1
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4
36 Antipyretics Phase 4,Phase 2,Phase 3
37 Cyclooxygenase Inhibitors Phase 4
38 Fibrinolytic Agents Phase 4
39 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
40 Platelet Aggregation Inhibitors Phase 4
41 Antimalarials Phase 4,Phase 3,Phase 2
42 Autoantibodies Phase 4,Phase 2,Phase 3
43 Omega 3 Fatty Acid Nutraceutical Phase 4
44
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
45
Diphenhydramine Approved Phase 2, Phase 3 58-73-1, 147-24-0 3100
46
Histamine Approved, Investigational Phase 2, Phase 3 75614-87-8, 51-45-6 774
47
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
48
Promethazine Approved Phase 2, Phase 3 60-87-7 4927
49
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
50
Hydroxychloroquine Approved Phase 3,Phase 2 118-42-3 3652

Interventional clinical trials:

(show top 50) (show all 122)

id Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
3 Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus Completed NCT01769937 Phase 4 H.P. Acthar Gel
4 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
5 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
6 Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
7 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Recruiting NCT02270970 Phase 4
8 Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT01632241 Phase 4 Standard therapy
9 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
10 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
11 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT00424476 Phase 3 Placebo;Belimumab 1 mg/kg;Belimumab 10 mg/kg
12 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus Completed NCT00410384 Phase 3 Placebo;Belimumab 1 mg/kg;Belimumab 10 mg/kg
13 A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States Completed NCT00724867 Phase 3
14 CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus Completed NCT01395745 Phase 3 blisibimod;Placebo
15 A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057 Completed NCT00712933 Phase 3 belimumab
16 A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus Completed NCT00137969 Phase 2, Phase 3 Rituximab;Placebo;Prednisone;Acetaminophen;Diphenhydramine
17 Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Completed NCT00065806 Phase 3 Atorvastatin;Placebo atorvastatin
18 Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE Recruiting NCT02444728 Phase 3 Hydroxychloroquine;Cyclophosphamide;Azathioprine;Methylprednisolone
19 Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis Recruiting NCT01639339 Phase 3 Standard therapy
20 Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients Active, not recruiting NCT02119156 Phase 3 Belimumab
21 BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115 Active, not recruiting NCT01597622 Phase 3 Belimumab
22 GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia Active, not recruiting NCT01345253 Phase 3 Belimumab;Placebo
23 Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Active, not recruiting NCT02446899 Phase 3 Placebo
24 Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Active, not recruiting NCT02446912 Phase 3 Placebo
25 Hydroxychloroquine for Prevention of Recurrent Miscarriage. Not yet recruiting NCT03165136 Phase 3 Hydroxychloroquine;Placebo
26 Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis Suspended NCT01773616 Phase 3 Oral prednisolone;Rituximab;Mycophenolate mofetil;Methyl prednisolone
27 CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis Terminated NCT02514967 Phase 3 Blisibimod;Placebo
28 Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis Terminated NCT00430677 Phase 2, Phase 3 Corticosteroids (prednisone or prednisolone);Abatacept;Abatacept;Mycophenolate mofetil (MMF);Abatacept
29 TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Terminated NCT00368264 Phase 2, Phase 3 infliximab;placebo
30 CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis Withdrawn NCT02074020 Phase 3 Blisibimod;Placebo
31 Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis Withdrawn NCT00336414 Phase 3 cyclophosphamide-prednisone-azathioprine
32 Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis Unknown status NCT01662973 Phase 1, Phase 2
33 Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis Unknown status NCT01661842 Phase 1, Phase 2
34 A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02 Completed NCT00583362 Phase 2
35 Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT00071487 Phase 2 Placebo;Belimumab 1 mg/kg;Belimumab 4 mg/kg;Belimumab 10 mg/kg
36 Serologically Active, Clinically Stable Systemic Lupus Erythematosus Completed NCT00000421 Phase 2 Prednisone;Placebo
37 Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Completed NCT00660881 Phase 2
38 Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease Completed NCT00624351 Phase 2
39 Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Completed NCT00094380 Phase 1, Phase 2 CTLA4-IgG4m (RG2077);Cyclophosphamide
40 A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus. Completed NCT01031836 Phase 2 MEDI-545;MEDI-545;MEDI-545;MEDI-545;MEDI-545;MEDI-545 600
41 Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus Completed NCT01405196 Phase 2
42 Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone Completed NCT00119678 Phase 2 Abatacept;Placebo;Prednisone;Abatacept
43 A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus Completed NCT01283139 Phase 2
44 Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study Completed NCT00976300 Phase 2 Cyclosporine A;Cyclophosphamide
45 A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus Completed NCT01438489 Phase 2
46 Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. Completed NCT01838694 Phase 1, Phase 2 Placebo
47 Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects Completed NCT01534403 Phase 2
48 Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Completed NCT01449071 Phase 1, Phase 2
49 Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer Completed NCT01273805 Phase 2 Hydroxychloroquine
50 Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome Completed NCT01160666 Phase 2 Belimumab

Search NIH Clinical Center for Systemic Lupus Erythematosus 10

Genetic Tests for Systemic Lupus Erythematosus 10

Genetic tests related to Systemic Lupus Erythematosus 10:

id Genetic test Affiliating Genes
1 Systemic Lupus Erythematosus 10 29

Anatomical Context for Systemic Lupus Erythematosus 10

MalaCards organs/tissues related to Systemic Lupus Erythematosus 10:

39
Skin, Bone, Kidney, Bone Marrow, T Cells, B Cells, Monocytes

Publications for Systemic Lupus Erythematosus 10

Variations for Systemic Lupus Erythematosus 10

ClinVar genetic disease variations for Systemic Lupus Erythematosus 10:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 IRF5 IRF5, 5-BP INS, PROMOTER REGION insertion risk factor
2 IRF5 NM_001098629.2(IRF5): c.*555G> A single nucleotide variant risk factor rs10954213 GRCh37 Chromosome 7, 128589427: 128589427

Expression for Systemic Lupus Erythematosus 10

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 10.

Pathways for Systemic Lupus Erythematosus 10

GO Terms for Systemic Lupus Erythematosus 10

Sources for Systemic Lupus Erythematosus 10

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....